Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
We analysed diagnostic phase plasma levels of thymidine kinase (TK) and mutated p53 in 81 patients with malignant lymphoma. Forty-three (53%) patients had increased (> 10 U/l) TK activity whereas 30 (37%) were positive for the mutated p53 gene product. In general, patients with p53 mutation positive tumors tended to have higher TK activity than those without. Furthermore, patients with high-grade non-Hodgkin's lymphoma (NHL) showed almost a linear correlation (rs = 0.79) between plasma levels of mutated p53 and TK. We conclude that the monoclonal antibody assisted detection of mutated p53 gene product may prove a useful adjunct to the diagnostic procedures of malignant lymphomas.
Lehtinen
T
T
Department of Clinical Oncology and Pathology, Tampere University Central Hospital, Finland.
Aine
R
R
Kellokumpu-Lehtinen
P
P
Hakala
T
T
Lehtinen
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016158:Genes, p53 / Q000235:genetics; D006689:Hodgkin Disease / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D013937:Thymidine Kinase / Q000097:blood*; D016159:Tumor Suppressor Protein p53 / Q000097:blood* / Q000235:genetics
D016159:Tumor Suppressor Protein p53; D013937:Thymidine Kinase